Figure 7.

jetPEI nanocarrier-delivered anti-DCBLD2 siRNAs significantly inhibit tumor metastasis in a resistant LUAD mouse model. (a) jetPEI nanocarrier was used as the vehicle for DCBLD2-targeted siRNAs to inhibit DCBLD2 expression in vivo. Schematic of the nanoparticles (left panel); the timeline of drug administration (right panel). Pc9/cis-luciferase cells were orthotopically transplanted into nude mice to develop tumors (n = 6 for each group). Fourteen days after inoculation, jetPEI-nanoparticles containing scramble or DCBLD2-targeted siRNA were intravenously injected. Mice injected with 5% glucose served as a negative control group. Mice were intraperitoneally injected with 4.0 mg/kg cisplatin or an equivalent volume of PBS every 7 days. (b) The primary tumors in the right lung and the metastatic foci in the left lung were serially sectioned and then subjected to HE staining. The expression of DCBLD2, E-cadherin, and Vimentin was detected by IHC staining. Scale bar: 200 μm (left), 50 μm (right). (c,d) Bioluminescence imaging (c) was performed to detect metastasis, and quantitation of bioluminescence signals is shown in (d). * p < 0.05, t-test. DDP, refers to cis-diamminedichloridoplatinum (II), also known as cisplatin or cisplatinum.